By Chris Wack
YS Biopharma shares were up 10% at $1.37 after the company said its PIKA Rabies Vaccine has received Phase 3 clinical trial approval from the Drug Regulatory Authority of Pakistan.
The stock hit its 52-week low of $1.19 on Monday, and is down 87% in the past 12 months.
The company said the Phase 3 clinical trial will evaluate the safety and immunogenicity of its PIKA Rabies Vaccine in preventing rabies infection.
YS Biopharma has completed Phase 1 and Phase 2 clinical trials of its PIKA Rabies Vaccine in Singapore. Another Phase 1 trial was also conducted in China to confirm the optimum dose and regimen to be used. All three clinical trials have shown that the PIKA rabies vaccine is safe, tolerable and immunogenic.
YS Biopharma has also obtained approval to conduct Phase 3 clinical trials of the PIKA Rabies vaccine in Singapore.
Write to Chris Wack at [email protected]
Read the full article here